Ernest Mario, an influential industry leader, researcher and philanthropist who graduated from the Rutgers pharmacy school ...

GSK (GSK) reported its RSV vaccine Arexvy elicited a robust immune response in people aged 18 to 49 years who were at ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions - with a massive ...

GSK has announced a new collaboration with local university and medical researchers, while Editas Medicine has a deal to ...

We are delighted to welcome Dr. Barbato to Incannex as our Chief Medical Officer. With an established track record in directing drug development through late-stage clinical trials and multiple product ...

Exhibition concludes with 105,000 attendees confirmed over three days Winner of prestigious Vision NextGen startup competition revealed as X-Genome, ...

In a letter, advocates call for officials to hold long-term care facilities and nursing homes accountable for providing ...

GSK is presenting its case for broader use of its RSV vaccine with new data from a pair of studies in younger adults with ...

The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...

GlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which ...

World Business Council for Sustainable Development (WBCSD) is collaborating with leading companies in the sector, with support from PwC UK, to develop a Roadmap to Nature Positive for the ...